LY379268

LY379268 potently activates mGlu2/3 receptors, which act largely as presynaptic autoreceptors and heteroreceptors that inhibit glutamate release, making the compound a precise tool for reducing pathological hyperglutamatergic signalling. In addiction neuroscience it has been studied extensively for its ability to blunt drug-seeking behaviour. In rats and squirrel monkeys it dose-dependently attenuates cue-induced and priming-induced reinstatement of drug seeking, with a notably preferential effect on behaviour driven by drug-associated stimuli rather than primary reinforcement ^[1]. In squirrel monkeys it blocked nicotine self-administration and nicotine priming-induced reinstatement while having weaker effects on cocaine self-administration, and it potently reduced cue-induced reinstatement for both drugs ^[2].

Beyond addiction, LY379268 exhibits neuroprotective properties tied to reduced excitotoxicity. In studies of presynaptic autoreceptor function it distinguished mGlu2-preferring from mGlu3-preferring autoreceptors, and in a mouse model of demyelinating disease its administration restored impaired glutamate release regulation, pointing to a role for mGlu3-preferring autoreceptors in protecting against excitotoxic injury ^[3]. Its combination of anti-relapse and neuroprotective activity has made it a heavily used probe, even though translational development into an approved medicine was never completed. It is generally regarded as a mechanistic tool rather than a therapeutic product.

Preclinical evidence only, extensive and consistent in animal models

As a research compound, LY379268 has not undergone the human safety characterization required of a therapeutic, and tolerance to some of its behavioural effects has been observed with repeated dosing in animals. The broader mGlu2/3 agonist class has been associated with preclinical convulsion risk, which is relevant context for interpreting its profile. It is not approved for human use and should be considered strictly investigational.

LY379268 was created at Eli Lilly in the late 1990s as part of the same bicyclic amino acid program that produced eglumegad, offering even greater potency at group II receptors. It rapidly became a favourite tool for addiction and neuroprotection researchers worldwide and features in hundreds of preclinical studies. Unlike some siblings it was not advanced as a clinical candidate, instead serving as a benchmark agonist for probing mGlu2/3 biology.

Within neuroscience LY379268 is one of the most recognized and widely used mGlu2/3 agonists, especially esteemed in the addiction field for its consistent anti-relapse effects. It is frequently cited as evidence that group II metabotropic glutamate receptors are viable targets for substance use disorders and neuroprotection. It is known to researchers and informed enthusiasts as a mechanistic probe rather than a consumer compound.